Featured
PT-141 Nasal Spray or Troche? The Bottle Wins on Simplicity
The PT-141 nasal bottle wins for most people because administration takes seconds. Choose a troche when the nose or pump is the problem.
Read the guideRebody Blog
Hormones, recovery, and the evidence underneath them.
Reporting and practical guides on testosterone, sleep, energy, peptide policy, and the evidence behind claims you see online.
How the Rebody editorial team worksEditor’s picks
Featured articles
Featured
Rebody Blog
PT-141 Nasal Spray or Troche? The Bottle Wins on Simplicity
The PT-141 nasal bottle wins for most people because administration takes seconds. Choose a troche when the nose or pump is the problem.
Read the guide
Featured
Rebody Blog
GHK-Cu Cream vs Retinol: The Peptide-First Choice for Aging Skin
GHK-Cu is the peptide-first choice for skin renewal: a copper-binding tripeptide with human topical studies measuring firmness, density, thickness, wrinkles, pigmentation, and laxity.
Read the guide
Featured
Rebody Blog
Best Way to Take NAD+: Injection vs Nasal Spray vs Sublingual Tablets
Our pick for most people is NAD+ nasal spray: it is needle-free, room-temperature, and currently the lowest-priced Rebody format. The injection offers a defined eight-week course.
Read the guide
Featured
Rebody Blog
PCAC Day 2 Results: Epitalon Wins, DSIP Loses
PCAC voted 7–4–1 in favor of Epitalon and 6–7–1 against emideltide (DSIP). Semax remains pending.
Read the guide
Featured
Rebody Blog
BPC-157, KPV, and TB-500 Win Favorable PCAC Votes
BPC-157, KPV, and TB-500 won favorable PCAC votes, building momentum toward the 503A Bulks List and regulated peptide compounding.
Read the guide
Featured
Rebody Blog
16 Million BPC-157 Doses and Seven Complaints: The PCAC Testimony
Dr. Alex Tatem brought data covering more than 16 million BPC-157 doses to PCAC—along with seven complaints and no clear attributable adverse safety signal.
Read the guide
Featured
Rebody Blog
Dr. Alex Tatem’s TB-500 PCAC Testimony: The Full Case
Human thymosin beta-4 trials, nearly 190,000 compounded vials, empty FDA adverse-event searches, and a favorable 8–6–1 PCAC vote.
Read the guide
Featured
Rebody Blog
What Is PCAC? Why the July 2026 Peptide Vote Matters
PCAC put seven peptides and the 503A Bulks List in the national spotlight. Here is what the committee does and why the July 2026 votes matter.
Read the guide
Featured
Rebody Blog
PCAC’s Peptide Votes Put the 503A Bulks List in Focus
BPC-157, KPV, and TB-500 put the 503A Bulks List in the spotlight—and built momentum for peptide compounding through licensed pharmacies.
Read the guide
Featured
Rebody Blog
PCAC Peptides: The Full July 2026 List, Schedule, and Results
The complete July 2026 PCAC peptide list, two-day schedule, favorable BPC-157, KPV and TB-500 results, and official webcast links.
Read the guide
Featured
Rebody Blog
KPV Wins a Favorable PCAC Vote for the 503A Bulks List
KPV won a favorable PCAC recommendation for the 503A Bulks List, joining BPC-157 and TB-500 in a major Day 1 for peptide compounding.
Read the guide
Featured
Rebody Blog
PCAC Live Stream July 24: DSIP, Epitalon, and Semax Votes
Replay FDA's July 24 PCAC meeting on emideltide (DSIP), Epitalon, and Semax, with the agenda and links to verified results.
Read the guide
Featured
Rebody Blog
Emideltide (DSIP) Loses PCAC Vote 6–7–1
Emideltide—better known as DSIP—received an unfavorable 6–7–1 PCAC recommendation on July 24.
Read the guide
Featured
Rebody Blog
Epitalon Wins Favorable PCAC Vote 7–4–1
Epitalon received a favorable 7–4–1 PCAC recommendation on July 24, moving the nomination forward for FDA consideration.
Read the guide
Featured
Rebody Blog
Semax PCAC Vote: Focus and Cognitive Peptide Takes Center Stage
Semax closes PCAC Day 2 with separate free-base and acetate votes and a spotlight on neurological and cognitive peptide interest.
Read the guide
Featured
Rebody Blog
PCAC Day 2 Preview: DSIP, Epitalon, and Semax
PCAC Day 2 moves from sleep to longevity to cognition with DSIP, Epitalon, and Semax following a major opening day.
Read the guide
Featured
Rebody Blog
What Favorable PCAC Votes Could Mean for DSIP, Epitalon, and Semax
Favorable PCAC votes would move DSIP, Epitalon, and Semax toward the 503A Bulks List and regulated peptide compounding.
Read the guide
Featured
Rebody Blog
Three Peptides to Watch at Tomorrow’s PCAC Meeting
DSIP brings sleep. Epitalon brings longevity. Semax brings cognition. All three reach PCAC tomorrow.
Read the guide